BEYAZ Drug Patent Profile

When do Beyaz patents expire, and what generic alternatives are available?

Beyaz is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in BEYAZ is drospirenone; ethinyl estradiol; levomefolate calcium. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol; levomefolate calcium profile page.

DrugPatentWatch^® Generic Entry Outlook for Beyaz

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BEYAZ

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	63
Drug Prices:	Drug price information for BEYAZ
Drug Sales Revenues:	Drug sales revenues for BEYAZ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEYAZ
What excipients (inactive ingredients) are in BEYAZ?	BEYAZ excipients list
DailyMed Link:	BEYAZ at DailyMed

See drug prices for BEYAZ

See drug sales revenues for BEYAZ

Paragraph IV (Patent) Challenges for BEYAZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BEYAZ	Tablets	drospirenone; ethinyl estradiol; levomefolate calcium	3 mg/0.02 mg/ 0.451 mg and 0.451 mg	022532	1	2012-11-13

US Patents and Regulatory Information for BEYAZ

BEYAZ is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	AB	RX	Yes	Yes	11,617,751		Y
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	AB	RX	Yes	Yes	8,617,597		Y

Expired US Patents for BEYAZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	RE37564
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	5,798,338
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	RE38253
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	RE37838
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	7,163,931

International Patents for BEYAZ

See the table below for patents covering BEYAZ around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	735883
Norway	325495
South Korea	20070062964
World Intellectual Property Organization (WIPO)	0249675
Hungary	230299	Ösztrogén-ciklodextrin komplex tartalmú készítmények (Pharmaceutical compositions of estrogen-cyclodextrin complexes)

Supplementary Protection Certificates for BEYAZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
3632448	22C1031	France		PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 61678 20191016
0771217	CA 2006 00038	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
2588114	LUC00227	Luxembourg		PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022
3632448	LUC00266	Luxembourg		PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 61678, 20210401

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: BEYAZ

Last updated: July 27, 2025

---

Introduction

BEYAZ (drospirenone/ethinyl estradiol/levomefolate calcium) is a combination oral contraceptive approved by the U.S. Food and Drug Administration (FDA) primarily for pregnancy prevention. Market dynamics and the financial trajectory of BEYAZ encompass an intricate interplay of regulatory developments, competitive landscape, patent protections, evolving consumer preferences, and broader healthcare trends. This analysis aims to evaluate critical factors influencing BEYAZ's market positioning and forecast its financial prospects within the pharmaceutical landscape.

---

Regulatory Landscape and Patent Considerations

BEYAZ entered a competitive primarily branded oral contraceptive market leveraging FDA approval and patent protections that extend its market exclusivity. Its patent expiration dates, expected around 2025-2026, introduce potential generic competition, which could significantly impact sales volumes and margins. Notably, the combined formulation, which includes levomefolate calcium—a vitamin B9 supplement—differentiates BEYAZ from traditional oral contraceptives, providing a unique position with specific safety and efficacy claims.

Recent regulatory developments have focused on establishing safety profiles concerning thromboembolic risks associated with ethnic and racial demographics, affecting marketing and prescribing behaviors. Additionally, evolving guidelines for contraceptive use, including more comprehensive counseling on side effects and alternative options, could influence prescribing patterns.

---

Market Dynamics

Growth Drivers

• Rising Global Demand for Contraceptives: The increasing adoption of oral contraceptives driven by rising awareness around reproductive health and family planning globally fuels demand for products like BEYAZ.
• Enhanced Patient Acceptance: BEYAZ’s inclusion of levomefolate calcium can appeal to women concerned about folate intake, especially in regions with policies promoting supplementation for neural tube defect prevention.
• Partnerships and Market Expansion: Strategic alliances with healthcare providers and payers facilitate wider access. Expansion into emerging markets, especially via licensing agreements, offers considerable growth potential amid rising contraceptive uptake.

Competitive Landscape

• Generic Competition: As patent exclusivity diminishes, generic formulations from major pharmaceutical firms will erode market share. Generic oral contraceptives often significantly undercut branded counterparts on price, impacting revenue.
• Brand Differentiation and Niche Positioning: BEYAZ's unique formulation and perceived safety relative to older contraceptive options can sustain a niche, premium segment even post-patent expiry.
• Alternative Contraceptive Options: Advances in long-acting reversible contraception (LARC), such as intrauterine devices (IUDs) and implants, are increasingly favored, particularly among certain demographics, which may limit growth potential for oral contraceptives.

Pricing and Reimbursement Trends

Reimbursement policies and pricing pressures, notably from payers seeking cost-effective contraceptive solutions, influence market penetration. The integration of BEYAZ into formularies depends on demonstrating both clinical advantages and cost-benefit superiority relative to other contraceptives.

---

Financial Trajectory and Revenue Projections

Historical Performance

Historically, BEYAZ has achieved steady sales momentum, driven by its differentiated profile and effective commercialization strategies. According to IQVIA data, sales reached approximately $350 million in the U.S. in 2022, representing a consistent growth trend prior to patent expiration considerations.

Forecasted Trends

Post-patent expiration, revenues are expected to decline significantly due to generic erosion unless the manufacturer develops new formulations or indications. Conservative estimates project a 20-30% decline in annual sales within two years after patent expiry, contingent upon the competitive landscape and market acceptance of generics.

Impact of Patent Expiry and Generic Entry

Market analyses forecast generic entry beginning around 2025. Competition could reduce unit prices by 50% or more, leading to a sharp decline in revenue streams unless the company innovates or diversifies its portfolio. Strategic initiatives, such as developing extended-release formulations or combination therapies, could mitigate revenue loss.

Potential Growth Opportunities

• Line Extensions: Developing new formulations, such as lower-dose variants or contraceptives with additional health benefits.
• Expansion into New Markets: Growing contraceptive markets in Asia, Africa, and Latin America may offset U.S. revenue declines.
• Regulatory Approvals for Additional Indications: Broadening BEYAZ's use beyond contraception, such as management of premenstrual dysphoric disorder (PMDD) or acne, can enhance revenue streams.

---

Market Share and Competitive Positioning

Despite impending patent expiry, BEYAZ’s market share may stabilize due to brand loyalty, physician familiarity, and patient preferences for its unique folate-containing formulation. Nonetheless, generic competition is expected to erode market share, emphasizing the need for proactive lifecycle management strategies.

Financial Planning and Investment Outlook

Investors should consider the inherent risks posed by patent expiry, competitive pricing, and shifts toward alternative contraception methods. Companies planning to maximize BEYAZ’s lifecycle often invest in targeted marketing, patient education, and pipeline expansion to sustain revenue flows.

---

Key Market Challenges

• Patent Expiry and Generic Competition: Leading to revenue erosion.
• Market Preference Shift: Toward LARCs and non-oral contraceptive methods.
• Regulatory and Safety Perceptions: Ongoing safety evaluations may influence prescribing behavior.
• Pricing and Reimbursement Pressures: Impact overall revenue margins.

Strategic Recommendations

• Innovation: Develop new formulations or delivery systems to extend patent life.
• Expansion: Target emerging markets with growing contraceptive demands.
• Diversification: Broaden indications to encompass other gynecological or hormonal health issues.
• Patient Engagement: Leverage education to foster brand loyalty post-generic entry.

---

Key Takeaways

• BEYAZ’s market dominance is supported by its unique formulation, but impending patent expiry around 2025-26 poses significant revenue risks.
• The competitive landscape is intensifying with the likely entrance of generics, necessitating strategic innovation and diversification.
• Growth potential exists through market expansion, new indications, and formulation enhancements, especially outside the U.S.
• Price sensitivity, shifting consumer preferences toward LARCs, and regulatory safety concerns will influence its long-term financial trajectory.
• Proactive lifecycle management and diversification strategies are essential to maximize BEYAZ’s valuation during its post-patent period.

---

FAQs

Q1: When is the patent expiry for BEYAZ, and how will it impact sales?
The patent for BEYAZ is expected to expire around 2025-2026. Post-expiry, sales may decline substantially due to generic competition, potentially reducing revenue by up to 50-70% unless new formulations or indications are developed.

Q2: What differentiates BEYAZ from other oral contraceptives?
BEYAZ contains levomefolate calcium, a folate supplement, which provides additional benefits related to prenatal health, differentiating it from traditional contraceptives and potentially appealing to women conscious of folate intake.

Q3: How is the market for oral contraceptives evolving globally?
Global contraceptive demand is rising, especially in emerging markets driven by increased reproductive health awareness. However, preference is shifting in some regions toward long-acting reversible contraceptives (LARCs), which could impact sales of oral pills like BEYAZ.

Q4: What strategies can extend BEYAZ’s market life post-patent expiration?
Developing new formulations, exploring additional therapeutic indications, entering new geographic markets, and enhancing patient education can help sustain revenue streams beyond patent protection.

Q5: What are the key risks facing BEYAZ’s future financial performance?
Main risks include patent expiration leading to generic competition, shifts toward other contraceptive methods, regulatory safety concerns, and pricing pressures from payers and policymakers.

---

References

[1] IQVIA. (2022). U.S. Contraceptive Market Data.
[2] FDA. (2022). Approval and Regulatory Status of BEYAZ.
[3] Industry Reports. (2023). Global Contraceptive Market Trends.
[4] Patent Databases. (2023). Patent Timeline for BEYAZ.
[5] Healthcare Guidelines. (2022). Contraceptive Use and Safety Recommendations.